rs2108225 — SLC26A3 SLC26A3 Ulcerative Colitis Susceptibility Variant

Regulatory variant at the SLC26A3 locus associated with ulcerative colitis susceptibility — SLC26A3 encodes the DRA chloride/bicarbonate antiporter essential for intestinal epithelial barrier function and mucosal immune homeostasis

See your personal result for SLC26A3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC26A3 — The Intestinal Chloride Pump at the Heart of Mucosal Immunity

The SLC26A3 gene11 SLC26A3 gene
Solute Carrier Family 26 Member 3, also known as DRA (Down-Regulated in Adenoma) — a chloride/bicarbonate antiporter expressed at the apical membrane of intestinal epithelial cells and goblet cells encodes the intestine's primary chloride-absorbing transporter. By exchanging luminal chloride for intracellular bicarbonate across the apical membrane of colonocytes and goblet cells, SLC26A3 simultaneously drives chloride absorption and maintains the alkaline surface pH that protects the mucus layer, shapes the colonic microbiome, and gates mucosal immune activation. rs2108225 is a regulatory tag SNP22 regulatory tag SNP
A non-coding variant approximately 9 kb downstream of the SLC26A3 transcription end site — identified in a GWAS; likely in LD with a functional variant affecting SLC26A3 expression or regulation in intestinal tissue at the SLC26A3 locus identified in the first large-scale GWAS of ulcerative colitis in a Japanese population.

The Mechanism

SLC26A3/DRA operates as a Cl⁻/HCO₃⁻ antiporter33 Cl⁻/HCO₃⁻ antiporter
An antiporter moves two ions in opposite directions across the membrane simultaneously; DRA imports Cl⁻ while exporting HCO₃⁻, coupling chloride absorption to bicarbonate secretion on the apical (luminal) surface of intestinal epithelial cells. This exchange serves three interlocking functions: it absorbs chloride from the intestinal lumen (preventing chloride diarrhea), it secretes bicarbonate into the mucus layer (alkalinizing the mucosal surface pH), and — in goblet cells — it drives the bicarbonate-dependent expansion of mucin glycoproteins that form the mucus barrier.

When SLC26A3 activity is reduced, these three processes fail together. Studies in DRA-knockout and TNF-α-overexpressing mouse models44 Studies in DRA-knockout and TNF-α-overexpressing mouse models
Xiao et al. used TNF-α-transgenic mice with documented DRA downregulation; DRA null mice show severe chloride diarrhea with absent colonic bicarbonate secretion demonstrate that even mild colonic inflammation is sufficient to severely deplete DRA expression, producing a "strong defect in ileocolonic bicarbonate secretion" independent of changes to other ion transporters (CFTR, NHE3, NBC). The resulting acidified mucus layer creates a hostile environment for protective commensal bacteria that depend on alkaline pH, while favouring acid-tolerant pathobionts. A thinner, less-expanded mucus layer then exposes the epithelium directly to luminal microbial products, triggering pattern-recognition receptor activation and NF-κB-driven cytokine release.

The loop closes via reciprocal TNF-α/DRA regulation55 reciprocal TNF-α/DRA regulation
DRA knockdown increases TNF-α secretion from intestinal cells; TNF-α in turn dose-dependently suppresses DRA expression — a bidirectional circuit that can sustain mucosal inflammation once initiated. TNF-α suppresses DRA expression in intestinal epithelial cells, and DRA silencing elevates TNF-α secretion in the same cells. Risk allele carriers at rs2108225 may start with constitutively lower SLC26A3 expression or a steeper inflammatory-suppression response, making it easier for this feedback loop to become self-sustaining.

The Evidence

The primary evidence comes from a two-stage Japanese genome-wide association study66 two-stage Japanese genome-wide association study
Asano et al. (2009): Stage 1 — 1,384 UC cases and 3,057 controls on the Illumina Human610-Quad BeadChip; Stage 2 — independent replication cohort by Asano et al. (2009), which genotyped 1,384 Japanese individuals with ulcerative colitis and 3,057 controls across approximately 590,000 SNPs. The SLC26A3 locus reached genome-wide suggestive significance at p = 9.50 × 10⁻⁸ with an odds ratio of 1.32 (95% CI 1.19–1.47) per risk A allele — ranking it alongside FCGR2A and a chromosome 13q12 locus as one of three novel UC susceptibility signals identified in that study.

A Chinese case-control study77 Chinese case-control study
Shao et al. (2018) in International Journal of Colorectal Disease: 5 SLC26A3 polymorphisms typed in Chinese UC patients and healthy controls using SNaPshot genotyping; colonic tissue DRA expression assessed by qRT-PCR and immunohistochemistry confirmed that rs2108225 variation in SLC26A3 increases UC risk and is associated with altered DRA mRNA and protein expression in colonic tissue from UC patients, providing functional support for the GWAS finding. The mechanistic studies on DRA downregulation (PMIDs 21557395, 29286110) were conducted in cell and animal systems and are therefore indirect but biologically coherent evidence for the pathway.

The SLC26A3 UC signal has not been consistently replicated in large European IBD GWAS meta-analyses, which may reflect population-specific linkage disequilibrium patterns — the causal variant(s) at the locus may be in strong LD with rs2108225 in East Asian populations but not in Europeans.

Practical Actions

For risk A allele carriers, the actionable implication centres on protecting mucosal bicarbonate secretion and the gut epithelial barrier. Short-chain fatty acids (SCFAs)88 Short-chain fatty acids (SCFAs)
Butyrate produced by colonic fermentation of dietary fibre upregulates DRA expression in intestinal epithelial cells via histone deacetylase inhibition, directly increasing SLC26A3 activity — particularly butyrate — directly upregulate DRA expression in colonocytes, offering a dietary lever to compensate for genetically reduced SLC26A3 activity. Fermentable dietary fibre (inulin, resistant starch, pectin) that drives butyrate production by gut bacteria is a concrete, mechanism-specific intervention for this locus.

All-trans retinoic acid (ATRA)99 All-trans retinoic acid (ATRA)
The active form of vitamin A; it upregulates DRA by blocking IFN-γ-induced STAT1 phosphorylation, counteracting a key inflammatory suppression pathway for SLC26A3 blocks the IFN-γ/STAT1 pathway that suppresses DRA during inflammation, directly preserving SLC26A3 expression under inflammatory conditions. Adequate vitamin A status supports this ATRA-dependent DRA maintenance pathway.

Interactions

The three UC susceptibility loci identified by Asano et al. (rs2108225 at SLC26A3, rs1801274 at FCGR2A, and rs17085007 at 13q12) represent distinct biological pathways — innate epithelial barrier (SLC26A3), immunoglobulin receptor signalling (FCGR2A), and an unknown locus (13q12). Their combined contribution to UC risk is additive rather than synergistic, and no compound effect has been characterised in published literature.

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal

Two copies of the reference allele — standard SLC26A3 mucosal barrier function

You carry two copies of the G (reference) allele at rs2108225. This is the most common genotype in European populations, found in approximately 29% of individuals globally and about 31% in Europeans. Based on the GWAS evidence from Japanese populations, this genotype is not associated with elevated ulcerative colitis risk from this locus. Your SLC26A3 expression at the gut mucosa is not expected to be reduced by this regulatory variant.

AG Intermediate

One risk allele — modestly elevated susceptibility to ulcerative colitis via reduced mucosal DRA expression

SLC26A3 (DRA) is expressed at the apical membrane of colonocytes and goblet cells, where it drives chloride absorption and bicarbonate secretion simultaneously. Reduced SLC26A3 activity diminishes mucosal bicarbonate secretion, acidifying the mucus surface, impairing mucin expansion, and creating a permissive environment for dysbiosis and bacterial translocation. This genotype suggests a constitutively reduced reserve of SLC26A3 expression, making the mucosa somewhat more vulnerable to inflammation-driven DRA suppression.

AA High Risk

Two risk alleles — highest SLC26A3 locus UC susceptibility; mucosal bicarbonate secretion and barrier function warrant proactive support

Homozygous risk allele carriers at this locus have both copies of whatever regulatory element is tagged by rs2108225, providing maximum dose of the expression-reducing effect. DRA protein levels are already severely depleted in active UC patients compared to healthy controls (Ding et al. 2018) — the genotype may lower the threshold at which this depletion occurs. Reduced DRA means impaired mucosal bicarbonate secretion, an acidified mucus layer, reduced mucin expansion, increased microbiome dysbiosis, and heightened susceptibility to the TNF-α/DRA reciprocal suppression loop that sustains inflammation once initiated. The combination of genetic predisposition and acquired triggers (NSAIDs, antibiotics, severe infections) makes this group most vulnerable.